Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
February 2018
-
Media ReleaseAveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results– On track to request pre-BLA meeting with FDA in Q2 2018 – – Intends to initiate pivotal trial in SMA Type 1 in Europe and multi-national pre-symptomatic SMA study in the first half of…
-
Taking on obesity
Novartis is developing an experimental drug for weight loss.
-
Media ReleaseTreatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflationUltibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to…
-
Media ReleaseAveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating ResultsConference call and webcast on February 27 at 4:30 p.m. EST CHICAGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments…
-
Media ReleaseNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasisTwo thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1] Findings show absolute PASI <=1/…
-
Media ReleaseNovartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasisMajority of patients with scalp psoriasis on Cosentyx® (secukinumab) achieved clear skin (PSSI 90) at Weeks 12 and 24 and improved quality of life[1] Scalp psoriasis affects 60 million…
-
Media ReleaseNovartis forms alliance to develop medicines for treating infectious diarrheal diseaseNovartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis Cryptosporidiosis is the…
-
Media ReleaseSandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosisGlatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched…
-
Potential weight loss treatment takes shape with help from patients
Novartis researchers are partnering with advocacy groups to understand the stigma and challenges facing patients with obesity.
-
Media ReleaseNovartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasisUS label updated to include Cosentyx® (secukinumab) data in moderate-to-severe scalp psoriasis[1] - one of the difficult-to-treat types of psoriasis[2] Approximately half of all 125 million…
-
Compound designed to fight Alzheimer’s disease shows promise in the lab
The molecule restores the activity of neurons and neural circuits in a model of the disease.
-
Partnering for improved cancer care around the globe
Novartis works tirelessly with third-party organizations to improve access to cancer care.
Pagination
- ‹ Previous page
- 1
- …
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- …
- 152
- › Next page